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A B S T R A C T
Background: The proportion of people with relapsing-remitting multiple sclerosis prescribed disease modifying
treatments (DMTs) in the United Kingdom (UK) is considered low compared with other countries. There are
diﬀerences in DMT prescription rates between UK nations (England, Wales, Scotland, Northern Ireland). Despite
this, there has been little research into decision-making processes and prescribing practices.
Objective: To investigate views and experiences of neurologists prescribing DMTs and MS specialist nurses to
identify factors inﬂuencing prescribing.
Methods: Semi-structured interviews with 18 consultant neurologists and 16 specialist nurses from diverse
settings across the four UK nations. Data were analysed using thematic framework analysis.
Results: Prescribing practices are inﬂuenced by organisational prescribing “cultures”, informal “benchmarking”
within peer networks, and prior experience with diﬀerent DMTs. Health professionals diﬀer in their perceptions
of beneﬁts and risks of DMTs and personal “thresholds” for discerning relapses and determining eligibility for
DMTs. Prescribers in England felt most constrained by guidelines.
Conclusion: To achieve equity in access to DMTs for people with MS eligible for treatment, there is a need for
public discussion acknowledging diﬀerences in health professionals’ interpretations of “relapses” and guidelines
and perceptions of DMTs, variation in organisational prescribing “cultures”, and whether the prevailing culture
suﬃciently meets patients’ needs.
1. Introduction
Disease-modifying therapies (DMTs) reduce the rate of relapse in
relapsing-remitting multiple sclerosis (RRMS) (Oh and
O'Connor, 2015), and can therefore improve quality of life and lessen
the need for relapse management interventions (e.g. steroids, hospita-
lisation, neuro-rehabilitation). Accordingly, the Association of British
Neurologists (ABN) recommends that DMTs should be considered
promptly for all individuals with active RRMS (Scolding et al., 2015).
Despite this, people with RRMS in the United Kingdom (UK) are pre-
scribed DMTs considerably less frequently than patients in other Eur-
opean countries. For instance, 59% of people with RRMS in the UK were
prescribed DMTs in 2013 while prescribing rates ranged between 75%
and 91% in Sweden, Italy, Spain, Germany and France (Wilsdon and
Barron, 2014).
Some of this variation could be due to national diﬀerences in drug
approvals, prescribing guidelines, pharmaceutical funding, availability
of neurologists and healthcare infrastructure. However, surveys have
found substantial diﬀerences between regions within the UK in the
proportion of people with a relapsing form of MS who reported taking a
DMT (Dorning et al., 2013; Redfern-Tofts and Holloway, 2014). In
2016, 77% of survey respondents were taking a DMT in Northern Ire-
land, compared to just 49% in Wales, 56% in England and 57% in
Scotland (Redfern-Tofts and Holloway, 2014). This wide divergence
despite relative similarity in policies and systems suggests variation in
prescribing rates may be at least partly due to decisions made by in-
dividual prescribing centres.
There is also some evidence that treatment initiation may depend on
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the neurologists’ level of MS specialism (Kurtuncu and Tuncer, 2017),
but this is poorly understood in the UK context. Studies of clinicians’
perceptions of DMTs have not extended to investigating the link be-
tween views of these drugs and their propensity to prescribe them
(Heesen et al., 2010; Hanson et al., 2014; Heesen et al., 2017). Thus far,
no empirical research has been carried out in the UK or internationally
investigating factors inﬂuencing prescribing rates, and no qualitative
research has been conducted with MS health professionals to obtain
ﬁrst-hand accounts of factors aﬀecting their prescribing practice.
The aim of this study was therefore to investigate the views and
experiences of neurologists and specialist MS nurses who prescribe or
facilitate access to DMTs for people with RRMS, in order to elucidate
the range of factors inﬂuencing DMT prescribing. Importantly, the
present research recruited healthcare professionals from the four na-
tions making up the UK to allow investigation of diﬀerent experiences
around the country of factors inﬂuencing prescribing.
2. Materials and methods
Sites were selected purposively to include participants from all four
constituent countries of the UK, and a range of specialist and non-
specialist services. ABN guidance states individuals working in isolation
are likely to experience diﬃculty maintaining specialist skills
(Scolding et al., 2015) therefore a “specialist” service comprised at least
two consultant neurologists with expertise or special interest in MS.
Sites were identiﬁed using MS service maps (Multiple Sclerosis Society,
2018; Multiple Sclerosis Trust, 2018) and discussion with regional
clinical research advisors. All consultant neurologists prescribing DMTs
at selected sites were invited to participate. Subsequently, snowball
sampling was used to identify and invite appropriate MS specialist
nurses, who have regular interactions with both prescribing neurolo-
gists and patients, and so are often important contributors to pre-
scribing decisions and can provide unique insight into issues aﬀecting
patients’ access to DMTs and decision-making.
Interviews were conducted between November 2016 and March
2017 by the ﬁrst author. Most took place in participants’ usual places of
work, typically hospital or primary care settings, and two were con-
ducted by telephone. Interviews were audio-recorded and participants
provided written informed consent.
Audio-recordings were transcribed verbatim and identifying in-
formation removed. Anonymised, transcribed data were analysed using
a thematic framework approach (Gale et al., 2013). A subset of tran-
scripts were coded and indexed by a second researcher to improve re-
search rigour, and ﬁndings were discussed by the research team. Ethical
approval for this study was received from University of Manchester
Research Ethics Committee 4 (Ref. 16413).
3. Results
Thirty-four healthcare professionals participated, including 18
consultant neurologists (ConNs) (5 female) and 16 MS nurses (MSNs)
(14 female). Participants were recruited from 15 sites across the UK,
including 7 specialist MS services. Eleven interviews were conducted
with health professionals working in England, 8 in Scotland, 8 in
Northern Ireland, and 7 in Wales. Neurologists had spent between 1
month and 20 years at consultant level (mean=9.5 years, SD=6.8).
MS nurses had been working in the nursing profession for between 16
and 41 years (mean=29.9 years, SD=7.2), and as MS specialist
nurses for between 10 months and 22 years (mean=12.4 years,
SD= 6.1). The majority of participants were white British (n=29),
with three identifying as white ‘other’, and two as Asian or Asian-
British.
Interviews lasted 65 min on average (range= 31 to 102 min).
Qualitative data analysis resulted in ﬁve themes relating to factors in-
ﬂuencing prescribing decisions: 1) Prescribing guidelines; 2) Identifying
relapses; 3) Perceived risk and readiness to prescribe; 4) Familiarity and
prior experience; and 5) Peer networks and prescribing cultures.
3.1. Theme one: prescribing guidelines
Neurologists working in England described National Institute for
Health and Care Excellence (NICE) prescribing guidelines as mandatory
criteria which they were “obliged to follow” (P32, ConN, England). This
was particularly true given the recent introduction of the ‘Blueteq’
online system across the National Health Service (NHS) in England for
evidencing compliance with clinical commissioning criteria based on
NICE guidance and securing prior approval for funding of treatment:
“…we've got the new Blueteq System now which, if we request funding
we have to state that they fulﬁl NICE guidelines, so it's as simple as that.”
(P39, ConN, England)
Participants in Scotland, Wales and Northern Ireland had knowl-
edge of NICE guidelines and indicated they generally prescribed in line
with them. However, while some followed NICE guidelines “quite
strictly” (P02, ConN, Wales) others felt they had “a little bit more ﬂex-
ibility to use the medication that you think's most appropriate” (P05, ConN,
Wales) as regional regulatory authorities permitted use of DMTs in
broader circumstances than in England. Moreover, while interviewees
in England were held accountable for prescribing decisions at a national
level, those in other regions described justifying decisions instead to
local managers and health boards.
Furthermore, some prescribers in Scotland expressed that “guidelines
are guidelines, not really more than that” (P41, ConN, Scotland) and in-
stead indicated their priority was the welfare of the patient rather than
meeting recommendations based on cost-eﬀectiveness:
“…that almost moral judgment of whether you adhere to the guideline or
whether you do the best for the person in front of you… you can't be
shackled by worries about whether it's expensive, whether the health
board have approved it, whether it's fulﬁlling X guideline or Y.” (P36,
ConN, Scotland).
Overall, participants in Scotland, Wales and Northern Ireland
identiﬁed fewer restrictions on prescribing than their counterparts in
England in terms of which guidelines to follow and how restrictive
these guidelines were.
3.2. Theme two: identifying relapses
DMT eligibility criteria in prescribing guidelines are based on fre-
quency and severity of relapses, such as ‘two clinically signiﬁcant re-
lapses in the previous two years’ (National Institute for Health & Care
Excellence, 2014) or ‘two or more disabling relapses in one year’
(National Institute for Health & Care Excellence, 2007). Participants
noted that despite clearly written deﬁnitions, distinguishing relapses
from pseudo-relapses was not always straightforward:
“…if they've had a recent infection, is it a pseudo worsening or is it a
relapse triggered by infection? So yes, I think relapses deﬁnitely are a bit
of a mineﬁeld.” (P05, ConN, Wales)
Moreover, interviewees found the language of guidelines “open to
interpretation” (P22, ConN, Northern Ireland), particularly in terms of
deﬁning a ‘disabling relapse’:
“What is a disabling relapse? If you're a piano player and your left hand
goes numb well that might be disabling for you, but if my left hand went
numb for a few days it may well not be at all disabling for me.” (P22,
ConN, Northern Ireland)
Interviewees felt the imprecise language led to “individual biases”
(P25, ConN, England) and personal “thresholds” (P04, ConN, Northern
Ireland) in determining relapses, with one participant stating “how you
deﬁne a relapse… is probably the main driver of individual variation in
prescribing” (P30, ConN, Wales).
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Specialist nurses in particular emphasised the importance of face-to-
face clinical examinations at the time of suspected relapse in order to
accurately identify relapses and DMT eligibility:
“To be conﬁdent, the person really should be having a neurological ex-
amination to see what the diﬀerences are between that examination and
the previous examination and to get an accurate history as well.” (P10,
MSN, Wales)
Many sites oﬀered rapid access clinics or appointments to see these
people quickly, however some relied on “a telephone line and we would
assess most of it over the phone” (P08, MS Nurse (MSN), Northern
Ireland). Despite the relapse reporting routes on oﬀer some patients still
reported possible relapses retrospectively during scheduled review ap-
pointments, making accurate identiﬁcation of relapses and DMT elig-
ibility extremely diﬃcult.
3.3. Theme three: perceived risk and readiness to prescribe
Some neurologists described themselves as an “active prescriber”
(P36, ConN, Scotland) and “fairly aggressive when it's needed” (P01,
ConN, England), while others “took a more careful approach” (P03,
ConN, Northern Ireland), particularly when considering prescribing
higher risk DMTs.
Participants’ cautiousness or readiness to prescribe or recommend
DMTs to patients were linked to their concerns about the risks asso-
ciated with DMTs. Major worries were the known risks of serious side-
eﬀects, such as progressive multifocal leukoencephalopathy (PML) in
patients taking natalizumab, and the unknown long-term eﬀects of
these immunosuppressant medications, including potential eﬀects on
reproductive health and cancer risk:
“I really have concerns about people being over-treated… and the po-
tential implications for their health in the future. I really have concerns
about that.” (P21, MSN, England)
“What are the real risks of giving people these drugs over long periods of
time? And we don't know, do we? We all talk about the higher eﬀect of
these drugs. Well, what is the risk of cancer? No one knows.” (P36,
ConN, Scotland)
Another concern was lack of evidence about long-term eﬀectiveness
of DMTs on disability and disease progression. One neurologist who
said they “don't sell any of these treatments as wonder drugs”, stated:
“All they do is reduce the relapse a bit and I don't think they do anything
else… I don't believe that we have deﬁnite evidence that any of these
treatments slow progression of disease.” (P27, ConN, Scotland)
There was consensus that disease course in relapsing MS is highly
unpredictable making it “very diﬃcult to prognosticate” (P07, ConN,
Scotland) and to base treatment decisions on likely outcomes.
Accordingly, more cautious interviewees felt patients might naturally
do better than expected and should not be exposed to higher risk
treatments if not truly necessary:
“The risks worry me, and the uncertainty about what a particular per-
son's MS will turn out to be. So I can think of someone who looked like
they were going to have awful, awful, awful MS… and actually that
person's done really, really well despite never having had Tysabri,
Alemtuzumab or anything else.” (P27, ConN, Scotland)
In contrast, more ‘ready’ prescribers feared patients might do worse
than expected if under-treated:
“I don't want to see them two years down the line to put them on more
robust therapy, but by then they've had a couple of relapses and they
haven't fully recovered and I'm kicking myself.” (P32, ConN, England)
3.4. Theme four: Familiarity and prior experience
Participants reported the DMTs most commonly prescribed were
likely inﬂuenced by familiarity, prior experiences and how comfortable
they felt prescribing them. Familiarity was attributed to number of
patients prescribed the drug so far and whether the individual or service
had been involved in clinical trials prior to national licensing:
“You gain conﬁdence, you gain a service that's structured around the
infusions... So, I think that is a natural thing, that if you're a centre that's
been involved in a phase 3 study, quite often you end up using more of
that drug…” (P05, ConN, Wales)
“If it's just fresh from being licensed and you're not familiar with it at all,
you take a while to build up your experience and you start slowly… You
don't go and put ten people on a new drug that you've never used before.”
(P02, ConN, Wales)
Conﬁdence in prescribing and recommending DMTs was also said to
be inﬂuenced by the positive and negative outcomes of patients taking
the drugs:
“I was aware that one of the patients died. So when you see that sort of
thing, you're a bit more hesitant about using it.” (P09, ConN, England)
“It can be very possible so patients come back and say this drug's been
fantastic, it's really well tolerated and that'll sway us in a particular
way.” (P01, ConN, England)
3.5. Theme ﬁve: Peer networks and prescribing cultures
Interviewees discussed the importance of having access to a network
of peers prescribing DMTs, either within organisations or across re-
gions, for shared learning and achieving consensus on best approaches
to prescribing:
“We meet regularly once a year across [region] where we discuss all of
the MS treatments and things to make sure that we are quite similar in
our approaches.” (P02, ConN, Wales)
These networks seemed especially valuable to prescribers who
worked apart from other MS specialists:
“I didn't want to be out on a limb doing my own thing, I wanted to be in
with the group and I wanted to be able to benchmark myself against the
group.” (P04, ConN, Northern Ireland)
Peers inﬂuenced prescribing decisions at a local level through
shared practices and organisational ‘prescribing cultures’. In some
places, neurologists intentionally took a team approach as “you need to
make sure that you have a demonstrably standardised way of managing your
patients” (P32, ConN, England). In these organisations, multi-
disciplinary team meetings functioned to generate and maintain this
standardised practice and prescribing culture, as well as providing re-
assurance and alleviating concerns about prescribing ‘riskier’ DMTs:
“I feel reassured by the multidisciplinary thing, I think if I was working in
isolation I'd have more concerns about that [PML risk].” (P05, CN,
Wales)
However, at centres where prescribers considered themselves to be
a collection of individuals, neurologists were less inﬂuenced by their
peers:
“[Dr A] doesn't know what [Dr B] does in clinic. [Dr B] doesn't know
what [Dr C] does in clinic… Nobody really knows what other people do.”
(P41, ConN, Scotland)
One participant noted that shared prescribing practices came about
through local ‘habits’ and infrastructure:
“It's just what you become familiar with and if everybody else is doing it,
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the nurses are familiar with it, that's what you just end up using… It's just
what a centre is familiar with, and just habit. Learning from your peers.”
(P05, ConN, Wales)
Another clinician described how organisational prescribing cultures
could be driven by local opinion leaders:
“…you tend to have certain neurologists who are more dominant and
who inﬂuence the department, and if that neurologist or group of neu-
rologists have a certain view then that tends to purvey the department.”
(P36, ConN, Scotland)
4. Discussion
Interviews with neurologists and MS specialist nurses revealed a
number of factors inﬂuencing DMT prescribing decisions. The im-
portance of peer networks and prescribing cultures were emphasised,
with neurologists eager to position their decision-making in comparison
to local and national peers, often with the aim of aligning prescribing
practice. Neurologists reported prescribing more readily when they
were familiar with a particular drug and had positive experiences with
it in the past. However, some health professionals were more cautious
in prescribing or recommending DMTs due to uncertainty over long-
term beneﬁts and risks of DMTs, and uncertainty over necessity of
treatment given the unpredictable nature of the disease.
Prescribers found DMT eligibility criteria in national prescribing
guidelines open to interpretation, particularly in terms of deciding what
constitutes a disabling relapse, and some neurologists and nurses re-
ported diﬃculties in distinguishing new MS activity from pseudo-re-
lapses. Generally, neurologists in England felt most constrained by
guidelines. Prescribers in the other three UK nations had greater ﬂex-
ibility in the circumstances under which some DMTs can be prescribed
and experienced oversight by local rather than national regulatory
bodies, with which they had greater opportunity for dialogue.
The relative restriction in prescribing perceived by neurologists in
England could partly explain lower DMT prescribing rates in this UK
nation. However, this does not account for similarly low rates in
Scotland and Wales. It is possible that prescribing rates in the other
nations reﬂect shared attitudes within regional peer networks as pre-
scribing centres are few and largely interconnected, particularly in
Wales and Northern Ireland, resulting in a very small number of
dominant prescribing cultures.
There is some evidence from other ﬁelds of medicine that pre-
scribers’ personal beliefs about medicines predict prescribing practice
(Walker et al., 2001; Hutchinson et al., 2007). However, this requires
further exploration in multiple sclerosis care to quantify the extent to
which neurologists’ treatment perceptions inﬂuence their prescribing
practice.
The ﬁndings suggest a need to acknowledge individual diﬀerences
in health professionals’ attitudes to prescribing DMTs, and the impact of
these attitudes on patients’ access to treatment. While there is con-
tinuing debate around the long-term risks and beneﬁts of these drugs,
there is also consensus that these decisions should ultimately be
weighed up by the person with MS, as long as they fulﬁl the prescribing
eligibility criteria. Research into patients’ decision preferences indicates
that most people with MS prefer an active role in treatment decisions,
and advocate shared decision-making and informed choice
(Heesen et al., 2004). A substantial proportion may prefer a passive role
in decision-making, while very few would choose entirely autonomous
decision-making (Deber and Kraetschmer, 2007). However, preferences
may vary by nationality, age, level of education, and familiarity with
the condition (Deber and Kraetschmer, 2007; Solari et al., 2013).
Further work should be carried to out to support MS health pro-
fessionals to support informed patient decision-making according to
patients’ preferences, regardless of their personal views on the risks and
beneﬁts of treatment. Moreover, there is a need for more nuanced
deﬁnitions in guidelines for phenomena such as ‘disabling relapses’ and
observable standards by which to recognise them, to ensure their use-
fulness and practicability as eligibility criteria.
Existing prescriber networks could be strengthened and their utility
maximised through shared learning and experiences of DMTs in order
to increase prescribing conﬁdence across the network, as well as con-
sensus building, standardising practice and advocating for local service
provision. This might particularly beneﬁt those in smaller centres and
DMT-prescribing general neurologists who do not have ready access to
other prescribers or specialist MS knowledge.
Finally, it is important there is ongoing explicit and public discus-
sion acknowledging diﬀerences in organisational prescribing ‘cultures’
and habits, the impact of these on equitable access to DMTs regardless
of location, and the need to regularly query whether the local ‘culture’
suﬃciently meets patients’ needs. This may involve evaluating the
impact of multidisciplinary team meetings which have been advocated
in DMT prescribing guidelines for multiple sclerosis (Scolding et al.,
2015) and which are likely to drive shared thinking and practice. Sys-
tematic reviews investigating oncology treatment have found that over
a ﬁfth of cases discussed at multidisciplinary team meetings subse-
quently undergo changes in treatment plans, suggesting these forums
are key factors in therapeutic decision-making (Pillay et al., 2016; Basta
et al., 2017).
The present study has a number of strengths. Most importantly, it is
the ﬁrst to investigate inﬂuences on neurologists’ prescribing decisions
in the UK or internationally, and the ﬁrst to use qualitative methods
with MS health professionals to obtain ﬁrst-hand accounts of factors
aﬀecting DMT practices. The sample was large in size for a thematic
interview study (Braun and Clarke, 2013) and included MS specialist
nurses who are signiﬁcant contributors to prescribing decisions and
decision-making contexts. Further, interviews were carried out with
neurologists and nurses from each of the four nations of the UK, facil-
itating understanding of factors inﬂuencing prescribing across the UK
and diﬀerentially between areas of the UK. Some health professionals
may have been wary of disclosing views that conﬂicted with guidelines
or prescribing norms, but the frank and open responses obtained in the
interviews suggest this was not a major limitation. Future research
could expand on the present ﬁndings by quantifying the presence of the
identiﬁed factors inﬂuencing prescribing in representative samples of
DMT prescribers in the UK and in other nations with comparable
healthcare systems.
This research has shed light on the impact of individual health
professionals’ interpretations and perceptions and organisational pre-
scribing cultures on whether people with relapsing-remitting MS in the
UK are oﬀered DMT prescriptions. There is now a need to use this
knowledge to ensure equitable access to DMTs for all people with MS
who are eligible for treatment.
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